All In MedTech

FDA Clearance Tracker · P010031-S775

Amplia MRI CRT-D, Amplia MRI Quad CRT-D, Brava CRT-D, Brava Quad CRT-D, Claria MRI CRT-D, Claria MRI Quad CRT-D, Cobalt

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 11, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 11, 2022

Approved

Time to decision

25 days

Received Mar 17, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010031-S775
Device name
Amplia MRI CRT-D, Amplia MRI Quad CRT-D, Brava CRT-D, Brava Quad CRT-D, Claria MRI CRT-D, Claria MRI Quad CRT-D, Cobalt
Applicant location
Mounds View, MN
Received
Mar 17, 2022
Decided
Apr 11, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P010031

Device type

Device class
Class III

Every decision under product code NIK

FDA's approval statement

As written in FDA's record.

Approval for labeling updates to the clinical study summary for the post approval study.

Source documents

Other decisions for Medtronic Cardiac Rhythm Disease Management

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.